公开(公告)号：EP1863340A2

公开(公告)日：2007-12-12

申请号：EP06736637.7

申请日：2006-02-27

申请人： Genentech, Inc. ,  Lexicon Pharmaceuticals, Inc.

发明人： HORNER, Allison Anne Byers ,  CLARKE, Catherine Anne B. ,  COMBS, Katherin E. ,  DESAUVAGE, Frederic ,  EDWARDS, Joel ,  GODOWSKI, Paul ,  GRANT, Deanna ,  HUANG, Wenhu ,  KETCHERSIDE, Lorelei Diane ,  MASSEY, Erin Marie ,  MONTGOMERY, Charles A. ,  PAYNE, Bobby Joe ,  PETERSON, Andrew ,  QIAN, Ni Nancy ,  SCHRICK, Jeffrey L. ,  SHI, Zheng-Zheng ,  SPARKS, Mary Jean ,  STALA, Joy ,  VIATOR, Colleen M. ,  VOGEL, Peter ,  YE, Weilan ,  YEH, Jung-Hua ,  DING, Zhiyong

IPC分类号： A01K67/027 ,  C07K14/47 ,  C07K14/515 ,  C07K16/18 ,  G01N33/50 ,  C12N5/10 ,  A61K39/395

CPC分类号： C07K14/47 ,  A01K2217/075 ,  A61K2039/505 ,  G01N2500/00

摘要： The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO179, PRO181, PRO244, PRO247, PRO269, PRO293, PRO298, PRO339, PRO341, PRO347, PRO531, PRO537, PRO718, PRO773, PRO860, PRO871, PRO872, PRO813, PRO828, PRO1100, PRO1114, PRO1115, PRO1126, PRO1133, PRO1154, PRO1185, PRO1194, PRO1287, PRO1291, PRO1293, PRO1310, PRO1312, PRO1335, PRO1339, PRO2155, PRO1356, PRO1385, PRO1412, PRO1487, PRO1758, PRO1779, PRO1785, PRO1889, PRO90318, PRO3434, PRO3579, PRO4322, PRO4343, PRO4347, PRO4403, PRO4976, PRO260, PRO6014, PRO6027, PRO6181, PRO6714, PRO9922, PRO7179, PRO7476, PRO9824, PRO19814, PRO19836, PRO20088, PRO70789, PRO50298, PRO51592, PRO1757, PRO4421, PRO9903, PRO1106, PRO1411, PRO1486, PRO1565, PRO4399 or PRO4404 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.